Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 4c ; Offers Guidance

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.23, $0.04 better than the analyst estimate of $0.19. Revenue for the quarter came in at $156.79 million versus the consensus estimate of $145.28 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2025 revenue of $625-640 million, versus the consensus of $604 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours